Wip-ing out cancer

René Bernards

The Wip1 phosphatase is encoded by an oncogene that is amplified in several forms of human cancer, including breast cancer. Ablation of this gene confers resistance to breast tumors induced by certain oncogenes.

Cancer often results from a combination of activating mutations in growth-stimulatory genes (oncogenes) and inactivating mutations in growth-inhibitory genes (tumor-suppressor genes). Ideally, anticancer drugs should specifically inhibit the activity of the products of the oncogenes or reactivate the antiproliferative effects of the tumor-suppressor proteins. Such drugs would be more cancer-specific and have fewer side effects than the current generation of broad-specificity cytotoxic drugs. In spite of the difficulties in developing such designer drugs, the first successes have recently been reported^{1,2} and some have already reached the clinic with remarkable success. But which oncogene products are the best targets for the development of new anticancer drugs? On page 343–350 of this issue, Dmitry Bulavin and colleagues³ provide compelling evidence that inhibiting Wip1 may be a good strategy for treating certain types of cancer.

A brief history of Wip1

Wip1 is a serine-threonine phosphatase encoded by *Ppm1d*. It was first identified as a gene that is induced by the p53 tumor-suppressor protein in response to DNA damage⁴. The importance of the activation of this phosphatase by p53 became clear when it was found that Wip1 specifically inactivates the protein kinase p38 MAPK, which can activate p53 to cause cell cycle arrest and apoptosis in response to certain environmental stresses⁵. In addition, p38 MAPK can inhibit cell cycle stimulatory proteins, such as cyclin D1 and the Cdc25 phosphatases^{6,7}. Thus, *Ppm1d* activation by p53 seems to constitute a negative

Figure 1 The role of the Wip1 phosphatase in the response to stress signaling. Environmental stresses, such as ultraviolet radiation, activate the p38 MAPK protein kinase. This leads to the activation of a number of growth inhibitory proteins (indicated in red) and inactivation of growth-stimulatory proteins (green). The p53 tumor-suppressor protein activates several genes, including one that encodes the Wip1 phosphatase triggering a feedback inhibition loop to p38 MAPK.

feedback loop responsible for downregulation of genotoxic stress-induced signaling, which leads to suppression of the cellular stress response (Fig. 1).

As the p38 MAPK pathway is involved in negative regulation of cell proliferation, it is probably not surprising that overexpression of its inhibitor, Wip1, is seen in several forms of human cancer, including breast cancer^{8–10}. Also consistent with a role for Wip1 in cell proliferation is the finding that *Ppm1d* can cooperate with an activated *Hras* oncogene in transformation of primary mouse embryo fibroblasts¹¹ (MEFs). Conversely, Wip1-null MEFs have a reduced proliferative capacity *in vitro* and suffer from premature onset of senescence¹². Suppression of *Ppm1d* expression in neuroblastoma cell lines suppressed growth and induced apoptosis⁸. Together, these data establish Wip1 as a central component of the cellular stress response, whose inhibition enhances antiproliferative effects of environmental stress signals.

Multiple Wip1 targets

In the present study, Bulavin *et al.*³ studied the effects of loss of the Wip1 phosphatase *in vitro* and *in vivo*. They used fibroblasts derived from Wip1-null mouse embryos, which were previously shown to have a very limited *in vitro* lifespan due to premature onset of senescence. Consistent with the idea that Wip1 is required for negative regulation of p53 in response to certain stress signals, *Ppm1d*^{−/−} MEFs express elevated levels of the p53 target p21 (also called cip1; ref. 12). In spite of this, introduction of pairs of collaborating oncogenes, such as adenovirus *E1A* and *Hras*, restored normal proliferation rates in the Wip1-null cells, at least initially. But these *in vitro*-transformed cells were very poorly tumorigenic in nude mice. Subsequent analyses indicated that the transformed Wip1-null MEFs not only had elevated activity of p53 and its downstream targets, but also expressed higher levels of two additional tumor suppressors, p19 (also called Arf, an upstream regulator of p53) and p16 (also called Ink4a, an inhibitor of the cyclin D-CDK4-CDK6 protein kinases, which in turn are upstream regulators of the retinoblastoma (Rb) tumor-suppressor protein). Thus, deletion of *Ppm1d* activated two distinct tumor suppressors: the p53 and Rb pathways.

Which of these two pathways is more important in protecting Wip1-null cells from tumorigenesis? In a series of genetic experiments, the authors dissected the contribution of these two pathways to the antioncogenic effects of Wip1 loss. First, they generated MEFs deficient in both Wip1 and p53. Even though these Wip1-p53 double-knockout MEFs escaped the premature senescence response of the Wip1-null cells, they were still nontumorigenic when transformed with oncogenes, indicating that other antioncogenic pathways contribute to the transformation resistance of Wip1-null

René Bernards is in the Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam.
e-mail: r.bernards@nki.nl

cells. In contrast, MEFs that lacked Wip1, p19 and p16 were fully oncogenic when the oncogenes *Hras* or *Myc* were introduced. MEFs that lacked only Wip1 and p16 had an intermediate phenotype, as they were fully oncogenic when transformed by certain combinations of oncogenes, but not by others. The conclusion was that loss of Wip1 activates two tumor suppressor pathways, p19 and p16, both of which contribute to the resistance to transformation of cells lacking Wip1.

Living proof

Encouraged by the *in vitro* data, Bulavin *et al.*³ went on to ask if ablation of *Ppm1d* would inhibit oncogenesis *in vivo*. The authors decided to study breast cancer development, as Wip1-null mice have a strong induction of p16 in the normal mammary epithelium, and previous work indicated that the presence of cyclin D1 (whose action is inhibited by p16) is required for induction of breast cancer by certain oncogenes¹³. The authors crossed mice deficient for Wip1 with three different strains of mice, each engineered to overexpress a different oncogene in the epithelium of the mammary gland. Bulavin *et al.*³ found that

mammary tumorigenesis in mice that expressed the *Wnt1* oncogene in the mammary gland was not affected by the absence of Wip1, whereas mice that expressed either *Hras* or *ErbB2* in the breast epithelium were relatively resistant to the development of breast cancer in the absence of Wip1. Finally, the authors show that when treated with a specific p38 MAPK inhibitor, tumor-resistant Wip1-null mice that express *ErbB2* in the breast repressed expression of p16 and developed breast tumors. Together, these data indicate that the absence of Wip1 prevents breast cancer induction through constitutive activation of p38 MAPK, which in turn causes upregulation of the tumor suppressor p16 (Fig. 1).

Wip1 as a drug target

The present study indicates that inhibition of the Wip1 phosphatase could suppress the proliferation of certain types of cancer, most notably breast cancer. Phosphatases are, in principle, susceptible to targeting by drugs, as potent inhibitors of other phosphatases have been developed. The side effects of inhibition of Wip1 may also be acceptable, as Wip1-null mice develop normally, even though defects in

immune function have been noted¹². Not all types of cancer respond to antiproliferative signaling through the p16 or p19 tumor-suppressor pathways. Indeed, Bulavin *et al.*³ show that breast cancers caused by the *Wnt1* oncogene in mice are not inhibited by loss of Wip1. But a substantial fraction of breast cancers have increased expression of cyclin D1, and such tumors may benefit from Wip1 inhibition¹⁴.

1. Lane, D.P. & Fischer, P.M. *Nature* **427**, 789–790 (2004).
2. Druker, B.J. *Cancer Cell* **1**, 31–36 (2002).
3. Bulavin, D.V. *et al.* *Nat. Genet.* **36**, 343–350 (2004).
4. Fiscella, M. *et al.* *Proc. Natl. Acad. Sci. USA* **94**, 6048–6053 (1997).
5. Takekawa, M. *et al.* *EMBO J.* **19**, 6517–6526 (2000).
6. Lavoie, J.N., L'Allemand, G., Brunet, A., Muller, R. & Pouyssegur, J. *J. Biol. Chem.* **271**, 20608–20616 (1996).
7. Bulavin, D.V. *et al.* *Nature* **411**, 102–107 (2001).
8. Saito-Obara, F. *et al.* *Cancer Res.* **63**, 1876–1883 (2003).
9. Li, J. *et al.* *Nat. Genet.* **31**, 133–134 (2002).
10. Hirasawa, A. *et al.* *Clin. Cancer Res.* **9**, 1995–2004 (2003).
11. Bulavin, D.V. *et al.* *Nat. Genet.* **31**, 210–215 (2002).
12. Choi, J. *et al.* *Mol. Cell. Biol.* **22**, 1094–1105 (2002).
13. Yu, Q., Geng, Y. & Sicinski, P. *Nature* **411**, 1017–1021 (2001).
14. van Diest, P.J. *et al.* *Am. J. Pathol.* **150**, 705–711 (1997).

Shutting down Wnt signal–activated cancer

M Mark Taketo

New evidence suggests that Wnt signaling can be suppressed or further activated by upstream signals, even though the pathway seems to be constitutively activated by downstream mutations in cancer cells.

The Wnt signal pathways have key roles in embryonic development. Defects in the pathway have also been implicated in cancer of the colon and other organs^{1,2}. Two Wnt pathways have been identified: the canonical and noncanonical pathways. Activation of the canonical pathway induces transcription of a new set of genes through the β -catenin–T cell factor (TCF) complex, which regulates cell proliferation and differentiation¹. Activation of the noncanonical pathway does not require β -catenin signaling and controls cell movement during morphogenesis².

In the absence of Wnt ligands bound to their receptors, the cytoplasmic complex of APC and Axin provide a scaffold for GSK3 β

to phosphorylate β -catenin (Fig. 1a). Phosphorylated β -catenin is then rapidly degraded through the ubiquitin pathway. When Wnt ligands bind to the cell-surface receptor Frizzled (Fzd), they trigger the phosphorylation of a cytoplasmic effector, Dishevelled (Dsh), which then inhibits the activity of GSK3 β on the APC–Axin complex. Unphosphorylated, and therefore stable, β -catenin can then accumulate in the cytoplasm and form a complex with TCF in the nucleus, which initiates transcription of Wnt target genes (Fig. 1b).

Canonical Wnt signaling in cancer

Most colon cancers and other digestive cancers are associated with mutations in *APC*, *AXIN1* or *CTNNB1*, and ~90% of colon cancers are associated with defects in the canonical Wnt signaling pathway (Fig. 1c)¹. Mutant APC and Axin are unable to assist GSK3 β in phosphorylating β -catenin. Similarly, mutations that lead

to amino acid substitutions in the phosphorylated residues of β -catenin stabilize the protein. Either type of disruption causes constitutive signaling independent of the upstream signal from Wnt.

On page 417–422, Hiromu Suzuki and colleagues add a new twist to this simplistic view on the canonical Wnt pathway³. In an earlier paper, they isolated genes that were preferentially hypermethylated in human colon and gastric cancers⁴. Among them, they identified a family of secreted Fzd-related proteins (SFRPs) that can compete with Fzd for the Wnt ligands. Now, the authors report on experiments in which they expressed SFRPs in colon cancer cell lines carrying mutations in *CTNNB1* or *APC*. SFRP1, SFRP2 and SFRP5 suppressed Wnt-dependent transcription by ~60% (Fig. 1d). They then expressed *WNT1* in the β -catenin mutant cell line HCT116. Wnt pathway-dependent transcription was ~3 times

M. Mark Taketo is in the Department of Pharmacology, Kyoto University School of Medicine, Kyoto, Japan.
e-mail: taketo@mfour.med.kyoto-u.ac.jp